Harvesting valuable metabolites from biological dark matter

Bactobio is at the forefront of microbial research, leveraging advanced technologies to unlock the potential of previously unculturable microbes. By utilizing next-generation sequencing (NGS), the company analyzes microbial communities to understand their interactions and growth patterns. This is complemented by Design of Experiments (DoE) and automation, which streamline the process of studying these complex networks. Bactobio employs synthetic biology techniques to isolate and cultivate new microbial species, significantly expanding their microbial collection, which includes over 1,800 novel species. This collection represents a mere fraction of the vast diversity of microbes, with the goal of discovering new, effective, and biodegradable chemistries for applications in healthcare and agriculture.

The company’s innovative approach also incorporates bioinformatics and analytical chemistry to identify and screen for novel antimicrobials. By employing machine learning and chemoinformatics, Bactobio efficiently pinpoints compounds produced by their microbes that can target specific pathogens. Their discovery platform is designed to rapidly assess the potential of these compounds, focusing on those with real-world applications against human and plant diseases. Through these technologies, Bactobio aims to contribute to a safer and greener world by harnessing the untapped potential of microbial life.

United Kingdom

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. 

Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. 

Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

Bactobio

Company Details